Brief: Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results That Confirm Best-In-Class Potential

Immunovant

28/11/2023 12:35

Nov 28 (Reuters) - Immunovant Inc  IMVT.O :
    * ROIVANT ANNOUNCES POSITIVE IMVT-1402 INITIAL 600 MG MAD
RESULTS
THAT CONFIRM BEST-IN-CLASS POTENTIAL
    * ROIVANT SCIENCES LTD: RESULTS FROM 600 MG MAD COHORT FOR
IMVT-1402 SIMILAR TO PREVIOUSLY DISCLOSED RESULTS FROM 300 MG
MAD COHORT FOR IMVT-1402
    * ROIVANT SCIENCES LTD: IMVT-1402 WAS OBSERVED TO DELIVER
DOSE
DEPENDENT AND DEEP IGG REDUCTIONS SIMILAR TO BATOCLIMAB IN ITS
PHASE 1 STUDY
    * ROIVANT SCIENCES LTD: IMVT-1402 600 MG WAS OBSERVED TO
DELIVER
PLACEBO-LIKE IMPACT ON ALBUMIN AND LOW-DENSITY LIPOPROTEIN
CHOLESTEROL

Source text for Eikon:  ID:nGNX8ZWxPG 
Further company coverage:  IMVT.O 

 ((Reuters.Briefs@thomsonreuters.com;))